- Home
- KNRX vs CURX Comparison
KNRX vs CURX Comparison
Compare KNRX & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | CURX |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 9.4M |
| IPO Year | 2023 | 2024 |
Fundamental Metrics
Financial Performance| Metric | KNRX | CURX |
|---|---|---|
| Price | $1.17 | $5.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 26.4K | 23.1K |
| Earning Date | 06-12-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.18 |
| 52 Week High | $3.45 | $6.80 |
Technical Indicators
Market Signals| Indicator | KNRX | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 89.37 | 67.84 |
| Support Level | $0.35 | $3.91 |
| Resistance Level | $1.46 | $6.00 |
| Average True Range (ATR) | 0.11 | 0.48 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 75.71 | 82.67 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.